Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritonavir boosting of erlotinib pharmacokinetics in NSCLC
NL-OMON22639Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of erlotinib and ritonavir, sponsored by Netherlands Cancer Institute. Started Mar 2019; status: recruiting.
02
Drugs
erlotinibritonavir
Beyond the preview
Go deeper on NL-OMON22639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22639.